Rhuzdah Kit
Product Images NDC 59651-740

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rhuzdah (NDC 59651-740). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Norethindroneethinyl Fig1)

A bar chart depicting circulatory disease mortality rates per 100,000 women-years by age group, smoking status, and oral contraceptive use. Four categories are compared: nonsmoking ever-users, nonsmoking controls, smoking ever-users, and smoking controls, across age ranges 15-24, 25-34, 35-44, and 45 and older.*

FDA Label Image

Figure (Norethindroneethinyl Fig2)

A forest plot showing effect estimates (odds ratios/risk ratios) with confidence intervals from multiple studies on contraceptive use. The studies listed include the NICHD Women's Contraceptive Study (2002), French E3N cohort Study (2005), Shanghai Women's Health Study (2009), Nurses' Health Study II (2010), Oxford Family Planning Association Study (2013), and Danish Sex Hormone Register Study (2017). Each study's effect estimate is plotted on the horizontal axis ranging approximately from -1.5 to 2.0, with confidence intervals shown as horizontal lines intersecting the point estimates represented by dots.*

FDA Label Image

Figure (Norethindroneethinyl Fig3)

An instructional illustration for Rhuzdah (norethindrone and ethinyl estradiol tablets) showing a hand placing a peel-and-stick day label on a pill kit. The kit contains round tablets in a 4-row blister pack with light peach and green tablets, labeled by day of the week.*

FDA Label Image

Package Label-principal Display Panel -0.4 mg/0.035 mg (28 Tablets Pouch) (Norethindroneethinyl Fig4)

Packaging label for Rhuzdah norethindrone and ethinyl estradiol tablets, USP 0.4 mg/0.035 mg, a 28-day regimen oral contraceptive kit. The label indicates the pouch contains one blister card of 28 tablets and includes manufacturer details from Aurobindo Pharma Limited, distributed by Aurobindo Pharma USA, Inc.*

FDA Label Image

Package Label-principal Display Panel -0.4 mg/0.035 mg (6 X 28 Tablets) (Norethindroneethinyl Fig5)

Rhuzdah kit contains norethindrone and ethinyl estradiol tablets USP 0.4 mg/0.035 mg for oral contraception. The packaging label shows a 28 day regimen with 6 pouches each containing 28 tablets. It is distributed by Aurobindo Pharma USA, Inc. and manufactured in India. The label includes storage instructions and safety information.*

FDA Label Image

Chemical Structure (Norethindroneethinyl Str)

Chemical structures of norethindrone and ethinyl estradiol are shown, including their molecular formulas and molecular weights. Norethindrone is labeled with formula C20H26O2 and molecular weight 298.42, while ethinyl estradiol is labeled with formula C20H24O2 and molecular weight 296.40.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.